Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

Literature DB >> 20425571

Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

Abstract

Incretin mimetics offer a new modality in diabetes treatment. This modality is based on the effects of the naturally occurring glucoregulatory gut hormone glucagon-like peptide-1 (GLP-1), which counteracts several pathophysiologic traits in type 2 diabetes. GLP-1 receptor agonists with extended half-lives entailing fewer injections and presumably an improved throughout-the-day glycemic control are in clinical development. This article summarizes the physiologic effects of GLP-1; the effects of the already marketed GLP-1 analogues for daily dosing, exenatide and liraglutide; and reviews the presently published data (with emphasis on clinical pharmacokinetics, efficacy, and safety) on GLP-1 agonists, which currently are in development and intended for once-weekly dosing: albiglutide/albugon, CJC-1131, CJC-1134-PC, exenatide once weekly, and taspoglutide.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2010 PMID： 20425571 DOI： 10.1007/s11892-010-0102-x

Source DB: PubMed Journal: Curr Diab Rep ISSN： 1534-4827 Impact factor: 4.810

52 in total

1. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.

Authors: Dennis Kim; Leigh MacConell; Dongliang Zhuang; Prajakti A Kothare; Michael Trautmann; Mark Fineman; Kristin Taylor
Journal: Diabetes Care Date: 2007-03-12 Impact factor: 19.112

Review 2. Incretin-based therapies in type 2 diabetes: a review of clinical results.

Authors: Emanuele Bosi; Pietro Lucotti; Emanuela Setola; Lucilla Monti; Pier Marco Piatti
Journal: Diabetes Res Clin Pract Date: 2008-11-20 Impact factor: 5.602

Review 3. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.

Authors: Josephine M Egan; Angela Bulotta; Hongxiang Hui; Riccardo Perfetti
Journal: Diabetes Metab Res Rev Date: 2003 Mar-Apr Impact factor: 4.876

Review 4. Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

Authors: R Mentlein
Journal: Regul Pept Date: 1999-11-30

5. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro.

Authors: M A Tracy; K L Ward; L Firouzabadian; Y Wang; N Dong; R Qian; Y Zhang
Journal: Biomaterials Date: 1999-06 Impact factor: 12.479

6. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans.

Authors: H Larsson; J J Holst; B Ahrén
Journal: Acta Physiol Scand Date: 1997-08

7. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.

Authors: Ted Okerson; Ping Yan; Anthony Stonehouse; Robert Brodows
Journal: Am J Hypertens Date: 2009-12-17 Impact factor: 2.689

8. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.

Authors: Jessica E Matthews; Murray W Stewart; Erika H De Boever; Robert L Dobbins; Rebecca J Hodge; Susan E Walker; M Claire Holland; Mark A Bush
Journal: J Clin Endocrinol Metab Date: 2008-09-23 Impact factor: 5.958

9. Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells.

Authors: Luciene R Carraro-Lacroix; Gerhard Malnic; Adriana C C Girardi
Journal: Am J Physiol Renal Physiol Date: 2009-09-23

10. Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes.

Authors: C Kapitza; T Heise; P Birman; K Jallet; J Ramis; R Balena
Journal: Diabet Med Date: 2009-11 Impact factor: 4.359

13 in total

1. Structure-based stabilization of insulin as a therapeutic protein assembly via enhanced aromatic-aromatic interactions.

Authors: Nischay K Rege; Nalinda P Wickramasinghe; Alisar N Tustan; Nelson F B Phillips; Vivien C Yee; Faramarz Ismail-Beigi; Michael A Weiss
Journal: J Biol Chem Date: 2018-06-07 Impact factor: 5.157

10. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).

Authors: Bo Ahrén; Aniceto Leguizamo Dimas; Patrick Miossec; Stéphane Saubadu; Ronnie Aronson
Journal: Diabetes Care Date: 2013-03-27 Impact factor: 19.112

Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

1. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.

Review 2. Incretin-based therapies in type 2 diabetes: a review of clinical results.

Review 3. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.

Review 4. Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

5. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro.

6. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans.

7. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.

8. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.

9. Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells.

10. Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes.

1. Structure-based stabilization of insulin as a therapeutic protein assembly via enhanced aromatic-aromatic interactions.

Review 2. GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.

Review 3. Incretin therapy--present and future.

Review 4. Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.

5. GLP-1R activation for the treatment of stroke: updating and future perspectives.

Review 6. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.

7. Novel Agents for the Treatment of Type 2 Diabetes.

8. Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications.

Review 9. GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.

10. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).